17,261 trials
Children Requiring Sedation to Facilitate Laceration Repair
Primary: Median Time (Minutes) After Administration of Intranasal Midazolam Until Patient Achieves Minimal Sedation — 4.7; 4.3; 5.2 minutes
Chronic Lymphocytic Leukemia
Primary: Number of Adverse Events as a Measure of Safety and Tolerability — 8; 40; 7; 41 participants
Hypertension
Primary: Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 12 Weeks — -12.57; -8.90 mmHg — p=0.010
Renal Cell Cancer · Kidney Cancer
Primary: Number of Participants With Response to Treatment — 0; 3; 29; 23 participants
Dental Plaque and Gingivitis
Primary: Gingivitis Scores — 1.48; 1.57; 1.49 units on a scale — p=0.091
Tuberculosis
Primary: Number of Participants With Solicited and Unsolicited AEs — 11; 10; 20; 30 participants
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
Primary: Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 4, 8, 16, and 24 — 5.87; 0.02; 7.01; -0.65 Percentage Change of TMV — p=<0.001
Lymphocytic Leukemia, Chronic
Primary: Percentage of Participants With Death or Disease Progression — 24 percentage of participants
Myelofibrosis
Primary: The Primary Endpoint is Progression-free Survival. — 24; 11 participants
Pancreatic Neuroendocrine Tumors (pNET)
Primary: Stage 1 - Progression Free Survival (PFS) Rate Analysis at 16 Weeks as Per Local Radiology Review — 51.6 Percentage of participants
Esophageal Cancer
Primary: Complete Pathologic Response (pCR) — 36.6 percentage of participants
Recurrent Prostate Cancer · Stage I Prostate Cancer · Stage IIA Prostate Cancer
Primary: The Number of Patients With a PSA Decline of ≥50% — 0 participants
Carcinoma, Non Small Cell Lung
Primary: Progression Free Survival (PFS) — 16.23; 11.07 Months — p=0.009
Myasthaenia Gravis
Primary: Mean Change From Baseline for Quantitative Myasthenia Gravis (QMG) Score at Week 24 — -2.37; -4.21 Units on a scale — p=0.256